

Beijing, China, April 20, 2021

Sartorius strengthens footprint in China by opening new Customer Interaction Center in Beijing

- Expanded facility: New 7,500-square-foot Customer Interaction Center in Beijing, China
- Dedicated space for demonstration and factory acceptance testing of equipment

Sartorius, a leading international partner of life science research and the biopharmaceutical industry, is expanding its presence in China by opening a new Customer Interaction Center (CIC), located in the Shunyi District, Beijing. Today's opening marks the completion of the first phase of expanding the existing production facility in Beijing, with an additional space of 7,500 square feet now available for demonstrations and factory acceptance tests (FAT).

The CIC will enable Sartorius' Chinese customers to test, validate, and adjust the functionalities of upstream (e.g. bioreactors) and downstream (e.g. tangential flow filtration systems) equipment, prior to installation at their factories. Local customers, who had to travel to Germany or India to run FATs in the past, will significantly benefit from close proximity in the future, as well as from skilled experts with extensive experience in automation engineering, process consultancy, basic design, and project management.

"The opening of our Beijing Customer Interaction Center is another milestone for Sartorius in China. It will allow us to more intuitively display our products and services to domestic customers, and to respond to their needs more quickly," said Edison Zhu, Head of Operations BPS Systems China. "China is already one of the biggest markets for Sartorius and will become even more important in the next years."

In 2021, Sartorius will invest more than 400 million euros in the expansion of capacities around the world to meet the high demand from the growing biopharmaceuticals market. This year, the company has already opened comparable CICs in Marlborough, Massachusetts, USA, and Havant, UK. Sartorius intends to further expand its Beijing facility in the future, and the company is now offering a wide range of job vacancies. Sartorius currently employs more than 650 staff members in China.

Since starting production in its first Chinese facility in Beijing in 1996, Sartorius has been participating in the rapid development of China's lab products and biopharmaceuticals market. Other sites are located in Shanghai, Suzhou, and Hong Kong.

A profile of Sartorius

The Sartorius Group is a leading international partner of life science research and the biopharmaceutical industry. With innovative laboratory instruments and consumables, the Group's Lab Products & Services Division concentrates on serving the needs of laboratories performing research and quality control at pharma and biopharma companies and those of academic research institutes. The Bioprocess Solutions Division with its broad product portfolio focusing on single-use solutions helps customers to manufacture biotech medications and vaccines safely and efficiently. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies. In fiscal 2020, the company earned sales revenue of some 2.34 billion euros. At the end of 2020, nearly 11,000 people were employed at the Group's approximately 60 manufacturing and sales sites, serving customers around the globe.

Contact

Timo Lindemann
Corporate Communications
+49 (0)551.308.4724
timo.lindemann@sartorius.com
sartorius.com

Follow Sartorius on Twitter [**@Sartorius_Group**](#) and on LinkedIn.